Effect of IL-4 and IL-12 liposomal formulations on the induction of immune response to bovine herpesvirus type-1 glycoprotein D

Vaccine

Volumn 15, Issue 16, 1997, Pages 1753-1760

  Baca Estrada, M E ^a   Foldvari, M ^b   Snider, M ^a   Van Drunen Littel Van Den Hurk, S ^a   Babiuk, L A ^a  

^a UNIVERSITY OF SASKATCHEWAN   (Canada)

^b UNIVERSITY OF SASKATCHEWAN   (Canada)

Author keywords

IL 12; IL 4; Liposomes

Indexed keywords

HERPES VACCINE; INTERLEUKIN 12; INTERLEUKIN 4; LIPOSOME; VIRUS GLYCOPROTEIN;

ANIMAL EXPERIMENT; ARTICLE; BOVINE HERPES VIRUS; CONTROLLED STUDY; DRUG ACTIVITY; ENCAPSULATION; HELPER CELL; HERPES; HUMORAL IMMUNITY; IMMUNIZATION; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; ANTIBODY FORMATION; ANTIBODY SPECIFICITY; CATTLE; DRUG COMPOUNDING; EPITOPES; FEMALE; HERPESVIRUS VACCINES; HUMANS; INTERFERON TYPE II; INTERLEUKIN-12; INTERLEUKIN-4; LIPOSOMES; LYMPHOCYTE ACTIVATION; MICE; MICE, INBRED C57BL; VIRAL ENVELOPE PROTEINS; VIRAL VACCINES;

EID: 0030852485     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(97)00111-4     Document Type: Article

References (26)

1. Mosmann, T. R. and Sad, S. The expanding universe of T-cell subsets: Th1, Th2 and more. Immunology Today 1996, 17, 138-146.
2. Mule, J. J., McIntosh, J. K., Jablons, D. M. and Rosenberg, S. A. Antitumor activity of recombinant interleukin 6 in mice. Journal of Experimental Medicine 1990, 171, 629-636.
3. Castell, J. V., Geiger, T., Gross, V., Andus, T., Walter, E., Hirano, T., Kishimoto, T. and Heinrich, P. C. Plasma clearance, organ distribution and target cells of interleukin 6/hepatocyte-stimulating factor in the rat. European Journal of Biochemistry 1988, 177, 357-361.
4. Hughes, H. P. A., Campos, M., van Drunen Littel-van den Hurk, S., Zamb, T., Sordillo, L. M., Godson, D. and Babiuk, L. A. Multiple administration with interleukin-2 potentiates antigen-specific responses to subunit vaccination with bovine herpesvirus-1 glycoprotein IV. Vaccine 1992, 10, 226-230.
5. Abraham, E. and Shah, S. Intranasal immunization with liposomes containing IL-2 enhances bacterial polysaccharide antigen-specific pulmonary secretory antibody response. Journal of Immunology 1992, 149, 3719-3726.
6. Reddy, R., Zhou, F., Nair, S., Huang, L. and Rouse, B. T. In vivo cytotoxic T lymphocyte induction with soluble proteins administered in liposomes. Journal of Immunology 1992, 148, 1585-1589.
7. New, R. R. C., Influence of liposome characteristics on their properties and fate. In Liposomes as Tools in Basic Research and Industry, (Eds Philippot, J. R. and Schuber, F.). CRC Press, Boca Raton, FL, 1995, pp. 4-20
8. van Drunen Littel-van den Hurk, S., Parker, M. D., Massie, B., van den Hurk, J. V., Harland, R., Babiuk, L. A. and Zamb, T. J. Protection of cattle from BHV-1 infection by immunization with recombinant glycoprotein gIV. Vaccine 1993, 11, 25-35.
9. van Drunen Littel-van den Hurk, S., Van Donkersgoed, J., Kowalski, J., van den Hurk, J., Harland, R., Babiuk, L. A. and Zamb, T. A subunit gIV vaccine produced by transfected mammalian cells in culture, induces mucosal immunity against bovine herpesvirus 1 in cattle. Vaccine 1994, 12, 1295-1302.
10. Kowalski, J., Gilbert, S. A., van Drunen Littel-van den Hurk, S., Babiuk, L. A. and Zamb, T. J. Heat shock promoter-driven synthesis of secreted bovine herpesvirus glycoproteins in transfected cells. Vaccine 1993, 11, 1100-1108.
11. 125I to high specific activity. Biochimica Biophysica Acta 1971, 251, 363-368.
12. Foldvari, M., Biphasic liposomes. In Patent Application PCT/CA94/00409, US, 1993
13. Czerkinsky, C., Andersson, G., Ekre, H. P., Nilsson, L. A., Klareskog, L. and Ouchterlony, O. Reverse ELISPOT assay for clonal analysis of cytokine production. I. Enumeration of gamma-interferon-secreting cells. Journal of Immunological Methods 1988, 110, 29-36.
14. Babiuk, L. A., Wardley, R. C. and Rouse, B. T. Defense mechanisms against bovine herpesvirus: relationship of virus host cell events to susceptibility to antibody-complement lysis. Infection and Immunity 1975, 12, 958-963.
15. Wolf, S. F., Temple, P. A., Kobayashi, M., Young, D., Dicig, M., Lowe, L., Dzialo, R., Fitz, L., Ferenz, C., Hewick, R. M., Kelleher, K., Herrmann, S. H., Clark, S. C., Azzoni, L., Chan, S. H., Trinchieri, G. and Perussia, B. Cloning of cDNA for natural killer cell stimulatory factor, a heterodimeric cytokine with multiple biologic effects on T and natural killer cells. Journal of Immunology 1991, 146, 3074-3081.
16. Afonso, L. C. C., Scharton, T. M., Vieira, L. Q., Wysocka, M., Trinchieri, G. and Scott, P. The adjuvant effect of interleukin-12 in a vaccine against Leishmania major. Science 1994, 263, 235-237.
17. Wynn, T. A., Cheever, A. W., Jankovic, D., Poindexter, R. W., Caspar, P., Lewis, F. A. and Sher, A. An IL-12-based vaccination method for preventing fibrosis induced by schistosome infection. Nature 1995, 376, 594-596.
18. Ikemoto, K., Pollard, R. B., Fukumoto, T., Morimatsu, M. and Suzuki, F. Small amounts of exogenous IL-4 increases the severity of encephalitis induced in mice by the intranasal infection of herpes simplex virus type 1. Journal of Immunology 1995, 155, 1326-1333.
19. Gregoriadis, G. Immunological adjuvants: a role for liposomes. Immunology Today 1990, 11, 89-97.
20. Golumbek, P. T., Azhari, R., Jaffee, E. M., Levitsky, H. I., Lazenby, A., Leong, K. and Pardoll, D. M. Controlled release, biodegradable cytokine depots: a new approach in cancer vaccine design. Cancer Research 1993, 53, 5841-5846.
21. Anderson, P. M., Katsanis, E., Sencer, S. F., Hasz, D., Ochoa, A. C. and Bostrom, B. Depot characteristics and biodistribution of interleukin-2 liposomes: importance of route of administration. Journal of Immunotherapy 1992, 12, 19-31.
22. Bliss, J., Van Cleve, V., Murray, K., Weincis, A., Ketchum, M., Maylor, R., Haire, T., Resmini, C., Abbas, A. K. and Wolf, S. F. IL-12, as an adjuvant, promotes a T helper 1 cell, but does not suppress a T helper 2 cell recall response. Journal of Immunology 1996, 156, 887-894.
23. Schijns, V. E. C. J., Haagmans, B. L. and Horzinek, M. C. IL-12 stimulates an antiviral type 1 cytokine response but lacks adjuvant activity in IFN-γ-receptor-deficient mice. Journal of Immunology 1996, 155, 2525-2532.
24. Yoshimoto, K., Swain, S. L. and Bradley, L. M. Enhanced development of Th2-like primary CD4 effectors in response to sustained exposure to limited rIL-4 in vivo. Journal of Immunology 1996, 156, 3267-3274.
25. Keane-Myers, A., Maliszewski, C. R., Finkelman, F. D. and Nickell, S. P. Recombinant IL-4 treatment augments resistance to Borrelia burgdorferi infections in both normal susceptible and antibody-deficient susceptible mice. Journal of Immunology 1996, 156, 2488-2494.
26. Bosco, M., Giovarelli, M., Forni, M., Modesti, A., Scarpa, S., Masuelli, L. and Forni, G. Low doses of IL-4 injected perilymphatically in tumor-bearing mice inhibit the growth of poorly and apparently nonimmunogenic tumors and induce a tumor-specific immune memory. Journal of Immunology 1990, 145, 3136-3143.